Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Gülsüm Anderson, Margarete Gries, Noriyoshi Kurihara, Tadashi Honjo, Judy Anderson, Vera Donnenberg, Albert Donnenberg, Irene Ghobrial, Markus Y. Mapara, David Stirling, David Roodman, Suzanne Lentzsch

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC-4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFκ-B ligand/macrophage colony-stimulating factor-stimulated bone marrow cell cultures. Treating bone marrow cultures with CC-4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90% inhibition), indicating that CC-4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC-4047 was mediated by a shift of lineage commitment to granulocyte colony-forming units at the expense of granulocyte-macrophage colony-forming units. Further studies revealed that this shift in lineage commitment was mediated through down-regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.

Original languageEnglish (US)
Pages (from-to)3098-3105
Number of pages8
JournalBlood
Volume107
Issue number8
DOIs
StatePublished - Apr 15 2006

Fingerprint

Thalidomide
Osteoclasts
Down-Regulation
Derivatives
Bone
Osteogenesis
Bone Resorption
Multiple Myeloma
Cell culture
Granulocyte-Macrophage Progenitor Cells
Macrophage Colony-Stimulating Factor
Macrophages
Drug Delivery Systems
pomalidomide
Granulocytes
Bone Marrow Cells
Tumors
Stem Cells
Cell Culture Techniques
Bone Marrow

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., ... Lentzsch, S. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 107(8), 3098-3105. https://doi.org/10.1182/blood-2005-08-3450

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. / Anderson, Gülsüm; Gries, Margarete; Kurihara, Noriyoshi; Honjo, Tadashi; Anderson, Judy; Donnenberg, Vera; Donnenberg, Albert; Ghobrial, Irene; Mapara, Markus Y.; Stirling, David; Roodman, David; Lentzsch, Suzanne.

In: Blood, Vol. 107, No. 8, 15.04.2006, p. 3098-3105.

Research output: Contribution to journalArticle

Anderson, G, Gries, M, Kurihara, N, Honjo, T, Anderson, J, Donnenberg, V, Donnenberg, A, Ghobrial, I, Mapara, MY, Stirling, D, Roodman, D & Lentzsch, S 2006, 'Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1', Blood, vol. 107, no. 8, pp. 3098-3105. https://doi.org/10.1182/blood-2005-08-3450
Anderson, Gülsüm ; Gries, Margarete ; Kurihara, Noriyoshi ; Honjo, Tadashi ; Anderson, Judy ; Donnenberg, Vera ; Donnenberg, Albert ; Ghobrial, Irene ; Mapara, Markus Y. ; Stirling, David ; Roodman, David ; Lentzsch, Suzanne. / Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. In: Blood. 2006 ; Vol. 107, No. 8. pp. 3098-3105.
@article{ec5bc5a1ffb54a5b95e0fbbb01209c82,
title = "Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1",
abstract = "CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC-4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFκ-B ligand/macrophage colony-stimulating factor-stimulated bone marrow cell cultures. Treating bone marrow cultures with CC-4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90{\%} inhibition), indicating that CC-4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC-4047 was mediated by a shift of lineage commitment to granulocyte colony-forming units at the expense of granulocyte-macrophage colony-forming units. Further studies revealed that this shift in lineage commitment was mediated through down-regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.",
author = "G{\"u}ls{\"u}m Anderson and Margarete Gries and Noriyoshi Kurihara and Tadashi Honjo and Judy Anderson and Vera Donnenberg and Albert Donnenberg and Irene Ghobrial and Mapara, {Markus Y.} and David Stirling and David Roodman and Suzanne Lentzsch",
year = "2006",
month = "4",
day = "15",
doi = "10.1182/blood-2005-08-3450",
language = "English (US)",
volume = "107",
pages = "3098--3105",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

AU - Anderson, Gülsüm

AU - Gries, Margarete

AU - Kurihara, Noriyoshi

AU - Honjo, Tadashi

AU - Anderson, Judy

AU - Donnenberg, Vera

AU - Donnenberg, Albert

AU - Ghobrial, Irene

AU - Mapara, Markus Y.

AU - Stirling, David

AU - Roodman, David

AU - Lentzsch, Suzanne

PY - 2006/4/15

Y1 - 2006/4/15

N2 - CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC-4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFκ-B ligand/macrophage colony-stimulating factor-stimulated bone marrow cell cultures. Treating bone marrow cultures with CC-4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90% inhibition), indicating that CC-4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC-4047 was mediated by a shift of lineage commitment to granulocyte colony-forming units at the expense of granulocyte-macrophage colony-forming units. Further studies revealed that this shift in lineage commitment was mediated through down-regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.

AB - CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC-4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFκ-B ligand/macrophage colony-stimulating factor-stimulated bone marrow cell cultures. Treating bone marrow cultures with CC-4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90% inhibition), indicating that CC-4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC-4047 was mediated by a shift of lineage commitment to granulocyte colony-forming units at the expense of granulocyte-macrophage colony-forming units. Further studies revealed that this shift in lineage commitment was mediated through down-regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.

UR - http://www.scopus.com/inward/record.url?scp=33645736007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645736007&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-08-3450

DO - 10.1182/blood-2005-08-3450

M3 - Article

C2 - 16373662

AN - SCOPUS:33645736007

VL - 107

SP - 3098

EP - 3105

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -